iSpecimen Q3 revenue $2.8M (+8% YoY, +75% sequential); net loss $2.1M; cash burn persists

iSpecimen Inc.

2023-Q3 EPS reported -$0.89 revenue$7,353,090

Revenue of $2.8M for Q3 2023 vs $2.6M in Q3 2022; sequential growth of 75% from $1.6M in Q2 2023.
Net loss of $2.1M ($0.23 per share) improved from $3.1M loss ($0.35) in Q3 2022; 9-month loss $8.0M ($0.89).
Cash and securities totaled $5.6M as of Sept 30, 2023, down from $15.3M at Dec 31, 2022; cash burn $9.7M in 9M2023.
Unique customer organizations reached 603 (+26% YoY); registered users 7,326 (+15% YoY); supplier orgs 234.
CEO targets cash flow neutral by year end; launched Next-Day Quote and Cancer Sequencing Procurement Program.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

iSpecimen Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $2.8 million for the three-month period ended September 30, 2023, net income $2.1 million, or $(0.23) per share, EPS $(0.23) per share.

Period: the three and nine month periods ended September 30, 2023
Revenue: $2.8 million for the three-month period ended September 30, 2023
Net income: $2.1 million, or $(0.23) per share
EPS: $(0.23) per share
Result: reported results

Exact text from the filing

iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-113623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.